OSTX
6:00 AM
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
Trial Results • Phase 2MIB Agents Factor 2026 Osteosarcoma Conference presentation Thu, Jun 25, 2026ostherapies.com